Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
Because measles-specific antibody titer after vaccination is lower than after natural infection, there is concern that vaccinated persons may gradually lose protection from measles. To examine the persistence of vaccine-induced antibody, participants of a vaccine study in 1971, with documentation of antibody 1-7 years after vaccination, were followed up in 1997-1999 to determine the presence and titer of measles antibody. Of the 56 participants (77% were 2-dose recipients), all had antibodies detected by the plaque reduction neutralization (PRN) antibody assay an average of 26-33 years after the first or second dose of measles vaccine; 92% had a PRN titer considered protective (>1 : 120). Baseline hemagglutination inhibition antibody titer in 1971 strongly predicted follow-up PRN antibody titer (P<.001). Persistence of antibody in these primarily 2-dose recipients supports the current elimination strategy to achieve and sustain high population immunity with a 2-dose schedule.
Dine
Mark S
MS
Hutchins
Sonja S
SS
Thomas
Ann
A
Williams
Irene
I
Bellini
William J
WJ
Redd
Stephen C
SC
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008457:Measles / Q000276:immunology* / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D008459:Measles virus / Q000276:immunology*; D009500:Neutralization Tests; D014611:Vaccination; D010948:Viral Plaque Assay
D000914:Antibodies, Viral; D008458:Measles Vaccine